Valuation Novartis AG NYSE

Stocks

Market Closed - NYSE 16:00:02 2026-10-23 EDT			5-day change	1st Jan Change
151.12 ^USD	-3.30%		+0.33%	+9.61%

03:20am	Novartis Reports Positive Results from Late-stage Studies for Remibrutinib	MT
10-23	Novartis AG - Special Call

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	196,458	194,448	207,167	195,514	266,003	294,913	-	-
Change	-	-1.02%	6.54%	-5.62%	36.05%	10.87%	-	-
Enterprise Value (EV) ¹	204,649	203,482	219,178	213,458	289,870	326,555	323,612	317,211
Change	-	-0.57%	7.71%	-2.61%	35.8%	12.66%	-0.9%	-1.98%
P/E	8.2x	28.3x	14.1x	16.5x	19.2x	21.8x	18.3x	15.9x
PBR	2.9x	3.23x	4.41x	4.52x	5.73x	6.26x	5.84x	5.42x
PEG	-	-0.4x	0x	-1x	0.9x	-19.82x	1x	1.1x
Capitalization / Revenue	3.81x	3.85x	4.44x	3.78x	4.69x	5.13x	4.8x	4.53x
EV / Revenue	3.96x	4.03x	4.7x	4.13x	5.11x	5.68x	5.27x	4.87x
EV / EBITDA	11.2x	10.9x	12.2x	10.2x	12.4x	13.9x	12.8x	11.7x
EV / EBIT	12.3x	12.2x	13.4x	10.9x	13.2x	15x	13.7x	12.4x
EV / FCF	15.4x	17x	16.6x	13.1x	16.5x	20.2x	18.6x	16.2x
FCF Yield	6.49%	5.87%	6.01%	7.61%	6.07%	4.94%	5.38%	6.17%
Dividend per Share ²	3.36	3.5	3.823	3.856	4.762	4.366	4.567	4.748
Rate of return	3.83%	3.87%	3.79%	3.94%	3.44%	2.81%	2.94%	3.06%
EPS ²	10.71	3.19	7.15	5.92	7.21	7.131	8.496	9.762
Distribution rate	31.4%	110%	53.5%	65.1%	66%	61.2%	53.7%	48.6%
Net sales ¹	51,626	50,545	46,660	51,722	56,674	57,494	61,389	65,113
EBITDA ¹	18,246	18,613	17,937	21,006	23,415	23,434	25,380	27,132
EBIT ¹	16,588	16,665	16,372	19,494	21,889	21,806	23,706	25,592
Net income ¹	24,021	6,955	14,854	11,939	13,967	14,305	15,945	17,728
Net Debt ¹	8,191	9,034	12,011	17,944	23,867	31,642	28,699	22,298
Reference price ²	87.82	90.40	100.79	97.79	138.63	155.16	155.16	155.16
Nbr of stocks (in thousands)	2,237,092	2,150,980	2,055,460	1,999,270	1,918,792	1,900,715	-	-
Announcement Date	2/2/22	2/1/23	1/31/24	1/31/25	2/4/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	37.06x	13.1x	27.8x	0.54%	1,135B
JOHNSON & JOHNSON	38.61x	6.49x	18.27x	2.02%	635B
ABBVIE INC.	36.46x	8.38x	17.29x	2.41%	505B
ROCHE HOLDING AG	20.87x	5.11x	12.73x	2.56%	378B
MERCK & CO., INC.	105.89x	5.92x	25.41x	2.34%	358B
NOVARTIS AG	21.76x	5.68x	13.94x	2.81%	295B
ASTRAZENECA PLC	22.43x	4.53x	12.94x	1.95%	266B
AMGEN INC.	27.87x	7.16x	12.81x	2.3%	237B
GILEAD SCIENCES, INC.	-45.48x	6.98x	27.06x	2.11%	193B
Average	29.50x	7.04x	18.69x	2.12%	444.85B
Weighted average by Cap.	35.23x	8.29x	20.39x	1.8%